Home » RXKINETIX TO MOVE MUCOSITIS DRUG INTO PHASE III
RXKINETIX TO MOVE MUCOSITIS DRUG INTO PHASE III
RxKinetix has reported that it will move its investigational drug RK-0202 for the treatment of chemotherapy-induced oral mucositis into Phase III testing.
The company recently completed a Phase II trial of RK-0202 in patients with head and neck cancer. The trial successfully demonstrated the drug's efficacy, with patients receiving RK-0202 having statistically lower incidences of oral mucositis versus placebo.
In addition, significantly fewer patients on RK-0202 required the use of an external feeding tube compared with placebo. Patients receiving RK-0202 also had lower incidence of adverse events such as weight loss, anorexia, dry mouth, nausea and dehydration.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May